Novartis: starts two clinical trials with Cosentyx drug
(CercleFinance.com) - Novartis today announced the initiation of two clinical trials on psoriasis drug Cosentyx versus AbbVie's Humira and proposed biosimilar adalimumab for the treatment of two debilitating autoimmune diseases that present a high risk of loss of mobility.
The first head-to-head clinical trial in ankylosing spondylitis (AS) will investigate Cosentyx in slowing spinal bone damage versus biosimilar adalimumab. The study is currently recruiting patients.
Meanwhile, the trial versus Humira in psoriatic arthritis (PsA) will check Cosentyx's superiority at 52 weeks, Novartis said on Tuesday.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The first head-to-head clinical trial in ankylosing spondylitis (AS) will investigate Cosentyx in slowing spinal bone damage versus biosimilar adalimumab. The study is currently recruiting patients.
Meanwhile, the trial versus Humira in psoriatic arthritis (PsA) will check Cosentyx's superiority at 52 weeks, Novartis said on Tuesday.
Copyright (c) 2018 CercleFinance.com. All rights reserved.